iOrganBio, a company specializing in intelligent cell manufacturing, announced today the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates. He is Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology.
Dr. Rubin's pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His expertise will be instrumental in expanding iOrganBio’s platform for neurological applications, according to the company.
iOrganBio’s CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency, enabling scalable production for disease modeling, drug discovery, and cell therapy development. The platform integrates the company’s functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type.
“Dr. Rubin’s deep understanding of stem cell biology and his track record in translating academic discoveries into therapeutic candidates will be invaluable as we advance our platform for neurological disease modeling and cell therapy,” said iOrganBio’s leadership in the announcement. The company believes his guidance will help shape the strategic direction of their organoid and cell manufacturing technologies.
This appointment underscores iOrganBio’s commitment to advancing FDA-aligned New Approach Methodologies (NAMs) that reduce reliance on animal testing by providing more physiologically relevant human cell-based models. The company’s closed-loop manufacturing process uses AI to make real-time adjustments, ensuring consistent quality and biological fidelity.
For more information about iOrganBio and its platform, visit iOrgan.Bio.
